Navigation Links
Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that it has begun to market and distribute EMSAM(R) in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor (MAOI), which was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of major depressive disorder.

EMSAM previously was marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers. Manufactured by Mylan subsidiary Mylan Technologies Inc. (MTI), EMSAM is a registered trademark of Somerset Pharmaceuticals Inc. In July 2008, Mylan acquired Watson Pharmaceutical Inc.'s 50 percent interest in Somerset, making the proprietary research and development company a wholly-owned subsidiary of Mylan.

Dey President Carolyn Myers, Ph.D., said, "I am very pleased that we have the opportunity to bring the marketing and distribution of EMSAM back into the Mylan family of companies. EMSAM was developed by Somerset in collaboration with Mylan and is manufactured by MTI. Now, we can market and distribute this important product through our specialty division, Dey, and the entire supply and distribution process will benefit from additional efficiencies and cost synergies going forward."

Dey, a Mylan company, is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies. For more information on Dey or its products, please visit www.dey.com.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
4. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
5. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
6. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
7. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
8. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
9. Dental Implant Market Insights Webinar
10. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
11. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 18, 2017 , ... BidMed, LLC, announced it will hold a ... lab equipment from two different leading institutes. This highly specialized laboratory equipment is coming ... States. This 1-day online auction will take place on BidMed’s website http://www.bidmed.com ...
(Date:1/18/2017)... , Jan. 18, 2017 Shareholder rights ... investigation into whether the board members of CoLucid Pharmaceuticals, ... duties in connection with the proposed sale of the ... biopharmaceutical company that develops small molecules for the acute ... CoLucid announced it had signed a definitive merger agreement ...
(Date:1/18/2017)... , Jan. 18, 2017 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... or the "Company"), today announced that Cameron ... ("Kingsdale"), has resigned from its Board of Directors.  ... to securities regulations that have limited both his ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... for Balance™ GT soybeans. The new Balance™ GT Soybean Performance System will combine ... and isoxaflutole, the active ingredient in the new Balance® Bean herbicide. The Balance™ ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
Breaking Biology News(10 mins):